We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

76 hedge funds and large institutions have $211M invested in Biotech Acquisition Company Class A Ordinary Shares in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 8

44% more capital invested

Capital invested by funds: $146M → $211M (+$64.9M)

31% more funds holding

Funds holding: 58 → 76 (+18)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

Holders
76
Holders Change
+18
Holders Change %
+31.03%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
9
Reduced
10
Closed
8
Calls
$96K
Puts
–
Net Calls
+$96K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$11.3M
2
CM
Cohanzick Management
New York
+$7.84M
3
RA
RiverPark Advisors
New York
+$7.84M
4
Marshall Wace
Marshall Wace
United Kingdom
+$5.9M
5
WCMNY
Westchester Capital Management (New York)
New York
+$5.11M

Top Sellers

Rank Fund Capital Flow
1
SRCM
Sage Rock Capital Management
New York
-$5.59M
2
ACM
Atalaya Capital Management
New York
-$5.4M
3
MP
Mangrove Partners
Connecticut
-$2.92M
4
CC
Centiva Capital
New York
-$2.42M
5
PP
Paloma Partners
Connecticut
-$498K
Name Holding Trade Value Shares
Change 		Change in
Stake
RA
51
Ramius Advisors
New York
$984K +$982K +100,000 New
CCA
52
Castle Creek Arbitrage
Colorado
$983K – – –
Walleye Capital
53
Walleye Capital
New York
$930K +$928K +94,489 New
CP
54
Centerbridge Partners
New York
$918K -$66.3K -6,750 -7%
SSA
55
Schonfeld Strategic Advisors
New York
$909K +$416K +42,418 +85%
Walleye Trading
56
Walleye Trading
New York
$782K +$780K +79,480 New
DFCM
57
Dark Forest Capital Management
Puerto Rico
$732K – – –
Susquehanna International Group
58
Susquehanna International Group
Pennsylvania
$596K -$805 -82 -0.1%
OAC
59
OMERS Administration Corp
Ontario, Canada
$557K +$556K +56,628 New
YCM
60
Yakira Capital Management
Connecticut
$530K +$528K +53,818 New
LC
61
Littlejohn & Co
Connecticut
$492K – – –
JP Morgan Chase
62
JP Morgan Chase
New York
$492K +$491K +50,000 New
SCM
63
Segantii Capital Management
Hong Kong
$492K +$491K +50,000 New
WRBC
64
W.R. Berkley Corp
Connecticut
$483K – – –
NAM
65
Nexpoint Asset Management
Texas
$342K – – –
SCA
66
Salient Capital Advisors
Texas
$317K +$316K +32,175 New
KIM
67
Karpus Investment Management
New York
$246K – – –
Morgan Stanley
68
Morgan Stanley
New York
$204K +$204K +20,751 New
DIG
69
DeepCurrents Investment Group
New York
$174K +$174K +17,730 New
LCM
70
Landscape Capital Management
New Jersey
$157K – – –
HighTower Advisors
71
HighTower Advisors
Illinois
$118K -$13K -1,328 -10%
AA
72
Ancora Advisors
Ohio
$99K – – –
ACM
73
Atalaya Capital Management
New York
$68K -$5.4M -550,000 -99%
PCM
74
Penserra Capital Management
California
$30K +$30.8K +3,140 New
UBS Group
75
UBS Group
Switzerland
$26K +$11.1K +1,135 +77%
1 2
3
4

BIOT Hedge Fund Activity: Q4 2021 in Review

76 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q4 2021, worth a combined $211M — up 44% from $146M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new BIOT positions and 8 closed out — a net gain of 18 holders — while 9 added to existing stakes and 10 trimmed.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $11.3M. The largest seller was Sage Rock Capital Management, exiting entirely with an estimated $5.59M sold.

  • 76 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q4 2021, up from 58 in Q3 2021.
  • Funds reported $211M of Biotech Acquisition Company Class A Ordinary Shares stock for Q4 2021, up 44% quarter-over-quarter.
  • 26 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q4 2021 and 8 closed out, a net change of +18 holders.
  • The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q4 2021 was Aristeia Capital, an estimated $11.3M added.
  • The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q4 2021 was Sage Rock Capital Management, an estimated $5.59M sold.

Based on aggregated 13F filings for Q4 2021.